FAST thanks GeneTx Biotherapeutics and Dr. Scott Stromatt for offering insight on GTX-102, the investigational antisense oligonucleotide for the treatment of Angelman syndrome. A recording of this webinar is available below.

GeneTx intends to have additional details about the upcoming trial (inclusion/exclusion criteria, protocol, etc.) posted to by February 15th and will hold another webinar following the release of that information. FAST, ASF, FAST Canada and CASS will collect questions from the community in advance of the next webinar.